Fundraising Fox
Aileron Therapeutics
NASDAQ: RNTXCambridge, US · Founded 2025 · Delaware corporation · 17 employees on LinkedIn · 2 known investors
Find your way into Aileron Therapeutics
Sign up to see every warm intro you have to Aileron Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aileron Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aileron Therapeutics is a clinical-stage biopharmaceutical company developing peptide and protein-based therapies for rare lung and fibrosis diseases. The company is primarily advancing LTI-03, a peptide derived from the Cav1 protein for idiopathic pulmonary fibrosis, which has completed Phase 1b testing and is now in Phase 2 clinical development.
Founders & leadership
Board
Investors · 2
How we know: board seat on SEC Form D · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$68.2M disclosed across 3 rounds · 2014–2023
▶$18.3MraisedNov 2023 · 15 investors · BiotechnologyRule 506(b)
- Alan MussoDirector
- Reinhard J. AmbrosDirector
- Nolan Sigal, M.D., Ph.D.Director
- William FaireyDirector
- Josef H. von RickenbachDirector
- Manuel Alves-Aivado, M.D., Ph.D.Executive Officer, Director
- Brian Windsor, Ph.D.Executive Officer
- Susan L. DrexlerExecutive Officer
- Offering amount
- $18.3M
- Amount sold
- $18.3M
- Sales commissions
- $752.8K
- Placement agents
- Arcadia Securities, LLC, Clear Street LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.1MraisedJan 2017 · 11 investors · BiotechnologyRule 506(b)
- Manuel AivadoExecutive Officer
- Caleb WinderDirector
- Seth L. HarrisonDirector
- John H. McArthurDirector
- Reinhard J. AmbrosDirector
- Joseph A. Yanchik IIIExecutive Officer, Director
- Brian M. Gallagher, Jr.Director
- Armen ShanafeltDirector
- Scott KapnickDirector
- Offering amount
- $40M
- Amount sold
- $30.1M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.8MraisedOct 2014 · 13 investors · BiotechnologyRule 506(b)
- Joseph A. Yanchik IIIExecutive Officer, Director
- Seth L. HarrisonDirector
- Brian M. Gallagher, Jr.Director
- Armen ShanafeltDirector
- Reinhard J. AmbrosDirector
- Scott KapnickDirector
- John H. McArthurDirector
- Enrico PetrilloDirector
- Offering amount
- $33M
- Amount sold
- $19.8M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Aileron Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Aileron Therapeutics do?
- Aileron Therapeutics is a clinical-stage biopharmaceutical company developing peptide and protein-based therapies for rare lung and fibrosis diseases. The company is primarily advancing LTI-03, a peptide derived from the Cav1 protein for idiopathic pulmonary fibrosis, which has completed Phase 1b testing and is now in Phase 2 clinical development.
- Who are Aileron Therapeutics's investors?
- Aileron Therapeutics's investors include Excel Venture Management, Novartis Venture Fund.
- How much funding has Aileron Therapeutics raised?
- Aileron Therapeutics has disclosed $68.2M raised across 3 rounds.
- Where is Aileron Therapeutics headquartered?
- Aileron Therapeutics is headquartered in Cambridge, US.